Several breakthroughs have been made to reduce HF due to MI, such as administering angiotensin-converting enzyme (ACE) inhibitors, β-receptor blocking agents, and aldosterone receptor antagonists, but the prevalence of HF in MI patients is still high [5, 6]. The gene discussed is ACE; the disease is hydrops fetalis.